We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sedia Biosciences Launches Cost-Competitive DNA Collection, Purification Kits

Sedia Biosciences Launches Cost-Competitive DNA Collection, Purification Kits

August 14, 2014

In vitro diagnostic and epidemiological test maker Sedia Biosciences has launched its Asante DNA Specimen Collection Kit and Asante DNA Purification Kit in the U.S. The kits are a cost-competitive alternative to current methods of DNA collection, the company says.

The collection kit features low DNA retention, few interfering substances and an easy-to-use design, according to Sedia. The collected samples are suitable for testing by most in vitro DNA amplification methods, including polymerase chain reaction and modifications, pretreatments and extensions, helicase-dependent amplification, ligase chain reaction and loop-mediated isothermal amplification, the company says.

The purification kit helps to simplify extraction, purification and concentration of DNA collected with the specimen kit by reducing the need for abrasive materials, chemical reagents or extreme concentration methods used by other DNA collector manufacturers, the Portland, Ore., company notes.

These features enable the company to produce the device at a lower cost and pass the savings on to its customers, says Ronald Mink, president and chief science officer.

As a Class I device, no FDA approval was required, Mink notes, adding the kits are registered with the FDA. Rollout, which has already begun, will be ramped up in the coming weeks, he says. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Commercial Operations

Upcoming Events

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 17Feb

    Effective Auditing for Manufacturing Quality

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • COVID-19

    Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

  • abbott-logo.gif

    Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

  • Fast Tack text

    FDA Gives MeiraGTx’s Achromatopsia Therapy Fast-Track Status

  • Australia_FlagonMap.gif

    TGA Investigates COVID-19 Tests and Emerging Variants

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing